Kornimate/medical-research-clean huggingface dataset:
hand training & brain changes

Conditions: Stroke; Hand Function

Summary: 10 participants with upper-limb impairment will be recruited from community sources. they will be invited to participate in a 15-day trial involving the iregained device. the study will involve 2 assessment visits to mcmaster, before and after the treatment, and 15 treatment visits. the data from the pilot study will be analyzed both quantitatively and qualitatively, as outcomes and explicit feedback from participants will be used to further optimize the device for future studies.

this pilot study will investigate the potential changes in the brain area controlling hand movement following 15 days of exercises to improve hand function in participants with upper limb impairments resulting from stroke. a device developed by dr. vineet johnson (iregained inc.) will be used to administer standardized exercises to improve hand function. to assess brain changes, transcranial magnetic stimulation pulses will be delivered to the motor cortex. the motor evoked potential (mep), a muscle response evoked from the tms, will be measured using electrodes on the hand. this study will test the feasibility of conducting motor therapy using this device while assessing potential changes in motor cortex function. findings from this study will contribute to developing treatment trials aimed at improving impaired limb function in stroke patients and quality of life in these individuals

Eligibility criteria:
inclusion criteria: -sustained a single stroke \>6months prior to start of study exclusion criteria: * severe spasticity or contractures (2 or less in the cmsa) * any other musculoskeletal or neuromuscular disorders that compromise sensation * prospective participants who are incapable of providing consent to participate in the research study will also be excluded (determined by an mmse score of 23 or less).

Keywords: hand function rehabilitation stroke rehabilitation motor control hand rehabilitation neurorehabilitation
a multicenter study: dexmedetomidine combined with sufentanil for patient controlled intravenous analgesia after caesarean section

Conditions: Postoperative Pain

Summary: the purpose of this multicenter study is to evaluate the effectiveness and safety of dexmedetomidine combined with sufentanil for patient-controlled analgesia after caesarean section


Eligibility criteria:
inclusion criteria: 1. parturients undergoing elective caesarean delivery under spinal anaesthesia 2. american society of anesthesiologists class i and ii parturients aged 18-45 years, with term singleton pregnancies 3. parturients with the ability to understand verbal and written mandarin 4. parturients who want to use pca intravenous analgesia and can use the pump correctly 5. parturients whose written informed consent have been obtained exclusion criteria: 1. a history of allergy to dexmedetomidine or other study drugs 2. a long use history of opioid analgesic, nsaids, tranquilliser use 3. psychiatric disorders 4. a history of neuromuscular and endocrine disease or allergic disease 5. a history of lower abdominal surgery 6. preoperative heart rate (hr) less than 50 bpm, sbp less than 100 mmhg or cardiac conduction or rhythm abnormalities 7. spinal anaesthesia was unsuccessful or an epidural catheter had to be used to achieve adequate anaesthesia 8. a second operation is required during the study. 9. participating other study during the latest three months 10. body mass index more than 30 kg/m2 11. difficult airway ( mallampati score more than 3 and anatomic deformity ) 12. not suitable for participation estimated by investigation
impulse control disorders in parkinson's patients treated with pramipexole and other agents (dominion study)

Conditions: Parkinson Disease

Summary: the purpose is to explore the frequency of impulse control disorders in parkinson's patients treated with different parkinson's medications.


Eligibility criteria:
inclusion criteria: observation criteria: male or female outpatients, aged 30 to 75 years of age, with idiopathic pd. patients must be selected on the basis of a prospective recruitment plan documented at the site, with the objective of obtaining an unbiased representative sample. patients must have been treated with anti-parkinson medication for a period of one year or greater and demonstrated a treatment response, in the opinion of the investigator. patients must be willing and able to comply with study procedures. patients must be willing and able to give meaningful, written informed consent. this must be completed prior to beginning any study procedures, in accordance with gcp and local legislation. exclusion criteria:
executive functions and preterm children in 11 to 12 year old

Conditions: Preterm Infant

Summary: preterm children have a high risk for neurodevelopmental impairments. the impact on motor functions and neurosensory functions is demonstrated but the incidence of executive functions is not described for preterm infants.

it is an epidemiologic, observational, prospective study. all patients, included in the lift cohort, in 11 to 12 year old during the period study, are contacted by mail. patients with congenital anomalies or genetic syndromes are excluded. children with parents who do not speak french are excluded. antenatal and postnatal criteria known to be associated with disorders of executive functions are collected as gestational age, sex, multiple pregnancy, intrauterine growth retardation, antenatal or postnatal steroid use, breastfeeding, cerebral injuries and socio-economic status. after a couple of weeks, parents are contacted by a study manager, by phone call, to collect parental consent and answer some parental questions. after consent collect, brief questionnaires are sending. if they wish, parents could give the brief teacher questionnaire to the mean teacher. teachers send by themselves their response. an informatic version is available with a personal link given especially by mail for each child. all data are anonymous. brief questionnaire is composed of 86 items, exploring 2 main domains: behavior and metacognition. twenty minutes are necessary to complete questionnaire. in case of no questionnaire return after one month, parents are contacted by phone. the investigators hypothesize a lost to follow-up at 0.25 and no response at 0.35. the response expected is 300 questionnaires.

Eligibility criteria:
inclusion criteria: * patient in 11 to 12 year old, included in lift cohort exclusion criteria: * congenital abnormalities including nervous system malformations; genetic diseases; incomplete understanding of written and oral french by parents
identification of the seventh cervical vertebra by palpation with neck rotation and side bending in patients with neck pain

Conditions: Identification of the Seventh Cervical Vertebra by Palpation

Summary: detect accuracy of that procedure in identification the seventh cervical vertebra, we aimed to determine accuracy of identification of the seventh cervical vertebra by palpation with neck rotation and side bending in patients with neck pain.

the ability to identify the correct vertebral level through examination is an important skill for clinicians in many different specialities (1,2). two methods for identifying seventh cervical vertebra are commonly used; the conventional palpation method, which identifies the most prominent cervical spinous process as the seventh cervical (c7) spinous process and flexion-extension method which identifies the lowest freely moving spinous process as c6 and the following stationary cervical spinous process as c7. one study found the accuracy of the conventional palpation method is 37.5% while the accuracy of the flexion-extension is 77.1%. another method is done by detecting the most prominent three vertebrae at cervicothoracic junction then three palpating fingers will be placed paravertebrally to the left of the cervicothoracic region against the left side of the assumed c7 and tl spinous processes. when rotation or lateral flexion is facilitated, c7 is expected to move significantly further than the more slowly reacting tl spinous process.

Eligibility criteria:
inclusion criteria: * neck pain, age (18- 60) male and female exclusion criteria: * with suspected ankylosing spondylitis, previous surgery on the cervical spine or congenital malformation of the cervical region.

Keywords: seventh cervical vertebra
clinical impact of the filmarray blood culture identification panel performed on positive blood cultures from intensive care patients with septicemia

Conditions: Septicemia

Summary: molecular testing is a largely validated approach allowing rapid identification of positive blood cultures. however, due to its high cost and its limited information on susceptibility, it is considered as an add-on technique reserved for specific patient populations. in our study, we specifically evaluated molecular testing in a critical care setting and measured its impact on the therapeutic management of critically ill with positive blood cultures. through the analysis of 110 positive blood culture episodes included in both pre- and post intervention period, we measured a drastic 14h-reduction of the time to administration of the optimal antimicrobial treatment with the use of the molecular approach.


Eligibility criteria:
inclusion criteria: * adult intensive care unit patients with positive blood cultures exclusion criteria: * palliative care patients

Keywords: filmarray bacteremia septicemia clinical impact molecular testing identification positive blood culture optimal antimicrobial treatment
arthroscopic trochleaplasty in chronic relapsing patellar dislocations: a follow-up study

Conditions: Patellar Dislocation

Summary: this study aims to evaluate the long-term clinical outcomes of arthroscopic trochleoplasty in patients treated for chronic recurrent patellar dislocations. the primary objective is to assess the effectiveness of the procedure in reducing the need for re-operations and preventing recurrent instability. secondary objectives include evaluating postoperative complications, patellofemoral pain, functional outcomes using the kujala anterior knee pain scale (akps), and quality of life measured by eq-5d-5l. this retrospective cohort study will analyze data from patient records and structured telephone interviews conducted at least one year post-surgery.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and older. * underwent arthroscopic trochleoplasty for chronic recurrent patellar dislocations. * surgery performed between 2015 and 2023. * availability of follow-up data and consent for participation. exclusion criteria: * concurrent knee surgeries unrelated to trochleoplasty. * previous surgeries on the same knee. * other significant orthopedic conditions affecting the knee. * lack of follow-up data or consent.

Keywords: patellar dislocation arthroscopic trochleaplasty
a study of tirzepatide (ly3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. the study will last approximately 47 weeks and may include about 12 visits.


Eligibility criteria:
inclusion criteria: * have been diagnosed with type 2 diabetes mellitus (t2dm) * have hba1c between ≥7.0% and ≤10.5% * be on stable treatment with unchanged dose of metformin \>1500 mg/day for at least 3 months prior to screening * be of stable weight (±5%) for at least 3 months before screening * have a body mass index (bmi) ≥25 kilograms per meter squared (kg/m²) at screening exclusion criteria: * have type 1 diabetes mellitus * have had chronic or acute pancreatitis any time prior to study entry * have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment * have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss * have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (alt) enzyme level \>3.0 times the upper limit of normal (uln) for the reference range, as determined by the central laboratory. participants with nonalcoholic fatty liver disease (nafld) are eligible for participation in this trial only if there alt level is ≤3.0 the uln for the reference range * have an estimated glomerular filtration rate \<45 milliliters/minute/1.73 m² (or lower than the country specific threshold for using the protocol required dose of metformin per local label) * have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months * have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2 * have been taking any other diabetes medicines other than metformin during the last 3 months * have been taking weight loss drugs, including over-the-counter medications during the last 3 months

Keywords: t2dm glp-1 ra glucose-dependent insulinotropic polypeptide (gip) glucagon-like peptide-1 (glp-1) gip/glp-1 dual receptor agonist
a phase 1/2 study to assess the safety, tolerability and pharmacokinetics of ngm621 in healthy subjects, and to assess the safety, pk and efficacy in subjects with moderate to severe ards caused by covid-19

Conditions: SARS-CoV-2 Infection

Summary: this study is a combined phase 1 and phase 2 study with iv infusion of ngm621 to evaluate the safety, tolerability, and pk in healthy volunteers (part 1), and safety, tolerability, pk and efficacy in subjects with confirmed sars-cov-2 infection (part 2).


Eligibility criteria:
inclusion criteria: * female subjects of childbearing potential must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result prior to dosing. * female subjects of childbearing potential and male subjects with a female partner of childbearing potential must use an effective method of contraception during the study, for at least 1 month following study completion, and must not plan to become pregnant for at least 1 month after her last study medication dose. * bmi 18-32 kg/m2 inclusive * ability to understand and provide informed consent * subjects confirmed with sars-cov-2 infection by pcr and hospitalized * if on mechanical support, less or equal than 2 days on mechanical ventilation or oxygenation exclusion criteria: * currently enrolled in another investigational protocol to treat sars-cov-2 infection * known history of complement deficiency * active infection with, or history of, compllicated pneumococcal or neisseria meningitis infection or history of unexplained, recurrent infection, within the last 60 days prior to dosing.
feasibility of a patient directed tool to assess heart health among endometrial cancer survivors

Conditions: Endometrial Cancer; Survivorship

Summary: investigators are conducting this study to find out more about what heart health means to participants and how healthcare providers can best help to manage heart health. participants will be asked to view an electronic tool designed to promote heart health awareness and help to manage heart health outside of the clinic. this study will provide important information to help investigators develop future programs that improve cancer patient's heart health after they complete their treatment.

primary objective: the primary objective of this pilot study is to assess the feasibility of enrolling and completing the heart health assessment among endometrial cancer patients scheduled for routine follow-up care. secondary objectives: * to assess patient satisfaction with the tool. * to identify the proportion of patients with non-ideal cardiovascular health scores who report initiating discussions regarding cardiovascular health during their routine oncology appointment.

Eligibility criteria:
inclusion criteria: * scheduled for a routine surveillance visit for pathologically confirmed stages i-iv endometrial cancer * greater than or equal to 3 months post-potentially curative cancer treatment * patients must be at least 18 years of age * have a working email address * comfortable reading medical information in english, as per self-report exclusion criteria: * currently receiving treatment (e.g. radiation, chemotherapy, immunological treatments for endometrial cancer) * have a history of endometrial cancer recurrence * enrolled in hospice care or documentation of life expectancy \< 6 months

Keywords: heart health
effectiveness of tktx cream on pain and fear in children during venipuncture: a randomized controlled trial

Conditions: Pain; Fear of Pain; Venipuncture Site Numbness

Summary: venipuncture, the process of obtaining blood samples for diagnostic purposes, is a common medical procedure performed worldwide. however, it can be associated with varying levels of pain and discomfort for patients. therefore, implementing effective pain management strategies during venipuncture is crucial to ensure patient comfort and improve the overall healthcare experience. this comprehensive overview aims to highlight the significance of pain management during venipuncture procedures. this study will investigate the effects of a pharmacological approach on the pain that children experience during venipuncture in a randomized trial. tktx topical anesthetic cream is a new commercially available product. in this study, the cream will be used for a shorter period of time than other creams used in previous studies, and it will also be free of side effects as they have been in previous studies with other creams.

venipuncture is a common medical procedure involving the insertion of a needle into a vein, often causing discomfort and pain. to alleviate this pain, pharmacological approaches have been widely explored. the efficacy of these approaches in managing venipuncture-related pain is of utmost importance for both healthcare professionals and patients. various pharmacological options have been studied, including topical anesthetics such as lidocaine creams or patches, local anesthetic injections like buffered lidocaine or ethyl chloride spray, and systemic analgesics such as nonsteroidal anti-inflammatory drugs (nsaids) or opioids. you may experience some pain, often a brief sting, when the needle is inserted into and removed from your arm. non-pharmacological pain intervention is a prophylactic and complementary approach to reduce pain. ensuring safety and efficacy when performing blood draws on pediatric patients, while also accounting for their emotional and physical well-being is of utmost importance. pharmacological intervention: topical anesthetics to reduce the discomfort generated by a venipuncture, the use of a topical anaesthetic cream is recommended prior to needle procedures, with options including emla (r), amethocaine and lidocaine. evaluating the effectiveness of these interventions requires considering factors like onset and duration of action, adequate pain relief achieved, patient satisfaction levels, and potential adverse effects.

Eligibility criteria:
inclusion criteria: * school-age children and * required needle procedures exclusion criteria: * neurodevelopmental problems * chronic disease * taken analgesic
effect of the insupatch on automated closed-loop glucose control in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this research study designed to look at how well adolescents' and young adults' blood sugars can be controlled with a "closed loop artificial pancreas" using a continuous glucose sensor, an insulin pump, and a computer program that automatically determines how much insulin to give based on the glucose level. the investigators will also study the effect of wearing a small heating patch, the insupatch, at the site of insulin infusion, on the ability of the closed loop system to control the blood sugar levels and to reduce the rise in glucose levels after meals.

this is an open-label, single-center, randomized crossover study evaluating the performance of a closed-loop (cl) insulin delivery system using a subcutaneous glucose sensor and an external insulin pump comparing the peak post-prandial glucose levels and the post-prandial glucose auc during either cl control alone or cl control with the insupatch in an inpatient hospital research unit (hru) setting. the closed loop visit consists of approximately 67 hours over 4 days and 3 nights.

Eligibility criteria:
inclusion criteria: 1. age 12-40 years 2. clinical diagnosis of type 1 diabetes 3. duration of type 1 diabetes ≥ 1 year 4. hba1c ≤ 9 % 5. treated with pump therapy for at least 3 months 6. body weight \> 40 kg exclusion criteria: 1. insulin resistant (defined as requiring \> 1.5 units/kg/day at time of study enrollment 2. presence of any medical or psychiatric disorder that may interfere with subject safety or study conduct 3. use of any medications (besides insulin) known to blood glucose levels, including oral or other systemic glucocorticoid therapy. inhaled, intranasal, or rectal corticosteroid use is allowed along as not given within 4 weeks of admission. use of topical glucocorticoids is allowable as long as affected skin area does not overlap with study device sites. subjects using herbal supplements will be excluded, due to the unknown effects of these supplements on glucose control 4. history of poor wound healing, heat sensitivity, or diminished skin integrity. 5. history of hypoglycemic seizure within last 3 months 6. anemic (low hematocrit), or evidence of renal insufficiency (elevated serum creatinine) 7. female subjects who are pregnant, lactating, or unwilling to be tested for pregnancy 8. subjects unable to give consent / permission / assent
the rechallenge of adcs in mbc patients

Conditions: Breast Cancer

Summary: to investigate the efficacy and safety of adc rechallenge


Eligibility criteria:
inclusion criteria: * age \> 18 years old. * diagnosed with metastatic breast cancer. * patients with prior exposure to adc (either in the adjuvant setting or metastatic disease are allowed). * patients plan to or have received adcs for the second or more time. * complete medical history was available. exclusion criteria: * medical history was incomplete

Keywords: antibody-drug conjugates metastatic breast cancer
topical preparation of pomegranate and ginkgo biloba for anti-aging activities

Conditions: Skin and Subcutaneous Tissue Disorders

Summary: as the quality of life improves, people are seeking to look as young as they feel. ginkgo biloba (gb) and pomegranate (pg) extract can be used to create efficacious topical anti-aging products. gb \& pg are now widely used in research and clinical trials on age-associated diseases, for example, skin aging, brain dysfunction, cardiovascular system diseases, carcinogen metabolism. the investigator's aim is to formulate a topical cream in the form (o/w or w/o emulsion) formulation, containing gb as an anti-aging formulation for the public.

in this study, a vanishing cream will be prepared by reaction of a stearic acid with alkali (naoh) to form stearate soap. then the gb extract will be added to the final form. the formulated cream will be characterized for identifying the type of emulsion, calibration curve for gb, drug content, irritation to skin, homogeneity test, ph, ft-ir test, ex vivo studies, physical stability, and human application. finally, a 9-questions questionnaire was published using google forms for the human volunteers.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of aging shape * follow up and collect data for a local and systemic activity of ginkgo biloba and pomegranate * the skin should be not injured as the cream can be easily applied * systemic oral capsule ginkgo biloba and pomegranate can be also given to enhance the activity as anti-aging activity exclusion criteria: * insulin-dependent diabetes * hypertension disease * skin wound